Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

Anticancer vaccination is a promising approach to increase the efficacy of cytotoxic T lymphocyte–associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) checkpoint blockade therapies. However, the landmark FDA registration trial for anti–CTLA-4 therapy (ipilimumab) revealed a complete l...

詳細記述

保存先:
書誌詳細
出版年:J Clin Invest
主要な著者: Hailemichael, Yared, Woods, Amber, Fu, Tihui, He, Qiuming, Nielsen, Michael C., Hasan, Farah, Roszik, Jason, Xiao, Zhilan, Vianden, Christina, Khong, Hiep, Singh, Manisha, Sharma, Meenu, Faak, Faisal, Moore, Derek, Dai, Zhimin, Anthony, Scott M., Schluns, Kimberly S., Sharma, Padmanee, Engelhard, Victor H., Overwijk, Willem W.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2018
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873868/
https://ncbi.nlm.nih.gov/pubmed/29480817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI93303
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料